Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Pegvisomant (Somavert) vs Teduglutide (Gattex)
An educational, source-based comparison of Pegvisomant (Somavert) and Teduglutide (Gattex) — how each peptide works, what it's researched for, and what to know before going deeper.
Pegylated GH receptor antagonist for acromegaly.
Genetically engineered analog of human GH with site-directed mutations blocking functional dimerization of the GH receptor; pegylation extends half-life. Lowers IGF-1 without lowering GH.
- Acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs
- • FDA-approved.
- • Monitor LFTs; tumor monitoring via MRI required.
- • Lipohypertrophy at injection sites.
GLP-2 analog for short bowel syndrome dependent on parenteral support.
Recombinant analog of glucagon-like peptide-2 with alanine→glycine substitution at position 2, resisting DPP-IV degradation; promotes intestinal mucosal growth, villus height, and absorptive capacity.
- Short bowel syndrome with intestinal failure
- Reduction of parenteral nutrition dependence
- • FDA-approved.
- • Colorectal polyp surveillance required.
- • Risk of intestinal obstruction and biliary/pancreatic disease.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Pegvisomant (Somavert) | Pegvisomant long-term acromegaly control | Lancet | 2001 | IGF-1 normalization in >90% on adequate doses. |
| Teduglutide (Gattex) | STEPS trial | Gastroenterology | 2012 | Reduced parenteral support volume in SBS patients vs placebo. |
Side-effect & safety grid
- FDA-approved.
- Monitor LFTs; tumor monitoring via MRI required.
- Lipohypertrophy at injection sites.
- FDA-approved.
- Colorectal polyp surveillance required.
- Risk of intestinal obstruction and biliary/pancreatic disease.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Pegvisomant (Somavert) vs Teduglutide (Gattex) — Key differences
- Class: Pegvisomant (Somavert) is classified as GH Receptor Antagonist · Endocrine, while Teduglutide (Gattex) is GLP-2 Analog · Gastrointestinal.
- Primary research focus: Pegvisomant (Somavert) — acromegaly inadequately controlled by surgery, radiation, or somatostatin analogs; Teduglutide (Gattex) — short bowel syndrome with intestinal failure.
- Tag: FDA-Approved · Endocrine vs FDA-Approved · GI.